Security
ACXP · Acurx Pharmaceuticals, Inc.
ACXPNASDAQCommon stockCurrentCIK 1736243Updated Sep 27, 2026
Name history
Acurx Pharmaceuticals, LLC · through Jun 23, 2021
ACXP price & chart
Loading TradingView…
NASDAQ:ACXP on TradingView ↗About the company
We are a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (“DNA”) polymerase IIIC, inhibiting DNA replication and leading to Gram-positive bacterial cell death. Our research and development pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin resistant Enterococcus and drug-resistant Streptococcus pneumoniae and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).
In the news
Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules News provided by Acurx Pharmaceuticals, Inc. Sep 03, 2025, 07:01 ET Share this article Share to X Share this article Share to X Acurx Maintains Listing on the Nasdaq STATEN ISLAND, ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,689,535Source | 3,857,963Source | 7,709,123Source | 9,376,706Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,420,943Source | 3,242,842Source | 3,042,438Source | 2,061,685Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,348Source | 17,031Source | 14,468Source | 11,628Source |
| Additional Paid in CapitalUSD | 80,554,738Source | 67,920,046Source | 57,871,070Source | 45,944,478Source |
| Retained Earnings (Accumulated Deficit)USD | -75,288,494Source | -67,321,956Source | -53,218,853Source | -38,641,085Source |
| Stockholders' Equity Attributable to ParentUSD | 5,268,592Source | 615,121Source | 4,666,685Source | 7,315,021Source |
| Liabilities and EquityUSD | 7,689,535Source | 3,857,963Source | 7,709,123Source | 9,376,706Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,420,943Source | 3,242,842Source | 3,042,438Source | 2,061,685Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -7,966,538Source | -14,103,103Source | -14,577,768Source | -12,092,776Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,247,401Source | 2,601,903Source | 3,206,527Source | 2,871,681Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,787,782Source | -10,383,431Source | -9,800,885Source | -7,542,290Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,637,169Source | 6,615,956Source | 8,163,322Source | 3,695,195Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 3,849,387Source | -3,767,475Source | -1,637,563Source | -3,847,095Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,556,100Source | 3,706,713Source | 7,474,188Source | 9,111,751Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 6,257,477Source | 8,699,267Source | 8,534,171Source | 7,338,505Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Investment Income, InterestUSD | 125,445Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -7,966,538Source | -14,103,103Source | -14,577,768Source | -12,092,776Source |
| Operating ExpensesUSD | 8,091,983Source | 14,103,103Source | 14,577,768Source | 12,092,776Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 3,695,182Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -8,091,983Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -7,966,538Source | -14,103,103Source | -14,577,768Source | -12,092,776Source |
| Earnings Per Share, BasicUSD per share | -5.32Source | -0.87Source | -1.15Source | -1.12Source |
| Earnings Per Share, DilutedUSD per share | -5.32Source | -0.87Source | -1.15Source | -1.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,498,793Source | 16,163,366Source | 12,671,572Source | 10,816,412Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,498,793Source | 16,163,366Source | 12,671,572Source | 10,816,412Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 6,257,477Source | 8,699,267Source | 8,534,171Source | 7,338,505Source |
| Investment Income, InterestUSD | 125,445Source | — | — | — |
| Operating ExpensesUSD | 8,091,983Source | 14,103,103Source | 14,577,768Source | 12,092,776Source |
| Research and Development ExpenseUSD | 1,834,506Source | 5,403,836Source | 6,043,597Source | 4,754,271Source |
Offerings
Registration 333-298801
Registration 333-295527
Registration 333-295528
Filing attachments
tm2611957d1_ex4-1.htm · 8-K · 2026-04-16
EX-4.1 2 tm2611957d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: _______ Issue Date: April 16, 2026 Initial Exercise Date: April 16, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte…
Read attachment ↗tm2611957d1_ex4-2.htm · 8-K · 2026-04-16
EX-4.2 3 tm2611957d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗tm2611957d1_ex99-1.htm · 8-K · 2026-04-16
EX-99.1 6 tm2611957d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants Staten Island, NY, April 16, 2026 - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“we” or “Acurx” or the “Company”), a late-stage biopharmaceutical company developing…
Read attachment ↗